Issaquah, WA--CaaMTech is taking strides toward creating a potent concoction of cannabinoids and psilocybin, positioning it at the forefront of innovative medical treatments. The lab's primary focus is understanding the interaction between these substances and their impact on physical and mental health.
According to an MJ Biz Daily report, their purifying efforts on a psilocybin-cannabinoid product are still nascent. The significant increase in genetic data about both substances has fueled the exploration of their potential synergies and eventual commercialization.
The report noted that preliminary studies hint at encouraging results, such as successfully reducing tumors in a 49-year-old breast cancer patient using a combination of cannabis and psilocybin. This observation bolstered the growing evidence supporting the therapeutic potential of cannabinoids and psychedelics in controlling tumor growth and relieving pain and distress associated with cancer treatments.
CaaMTech, along with other industry players, envisions an all-encompassing solution to grave mental health and inflammation issues using the properties of both substances. Cannabichromene (CBC), a minor cannabinoid abundant in the plant, might be a possible link between the two.
In the report, Canadian cannabis company Hexo Corp's CEO, Charlie Bowman, supports this approach, despite the challenges related to CBC's cultivation and synthesis. Daniel McQueen, executive director of the Center for Medicinal Mindfulness, also believes in the feasibility of a psilocybin-cannabis compound.
The development of this groundbreaking compound, however, is hindered by severe obstacles. Cannabinoids and psychedelics interact with different receptors in the brain, posing a challenge to their combination. Moreover, while certain studies have suggested that combining serotonin and a CB2 cannabinoid receptor may offer benefits, further research is necessary to substantiate these claims, as per the report.
Yet, the medical community's excitement for this potentially transformative compound is palpable. Combining cannabis and psychedelics could significantly relieve PTSD and traumatic brain injuries. The emerging evidence of overlap in receptor targets of these substances suggests new avenues for psychedelic-assisted therapy.
Notwithstanding the challenges and uncertainties, the relentless pursuit of better solutions for mental health issues continues. More in-depth research into how psychedelic drugs act in the brain remains a priority. Despite the hurdles, exploring cannabis and psychedelic-based medical treatments looks promising.
Learn more in the MJ Biz Daily report.